Skip to main content
. 2021 Oct 1;9(10):e003001. doi: 10.1136/jitc-2021-003001

Figure 5.

Figure 5

Programmed cell death ligand 1 (PD-L1) and CD8 immunohistochemistry (IHC) heterogeneity across indications. (A) Intratumoral CD8 T-cell density and (B) intratumoral stroma CD8 T-cell density across regions of each tumor by IHC H-score demonstrate that heterogeneity across regions may influence interpretations from single region analysis. (C) PD-L1-positive tumor cells across cases by IHC (SP263 clone) show that region-to-region variation in PD-L1 IHC signal can impact interpretation of immune phenotype for a tumor, but this would have impacted a treatment decision in only one urothelial bladder carcinoma (UBC) region that shows <25% of tumor cells positive. (D) The per cent of tumor area occupied by PD-L1-positive tumor-associated immune cells (immune cells present (ICP)) across cases were generally less heterogeneous but demonstrated large differences in a few regions. (E) Neoantigen load correlation to tumor intraepithelial CD8 levels assessed by H-scores across regions for each case lacked statistical significance. Neoantigen load is the number of neoantigenic mutations with evidence for expression in any tumor region.